M Andrew Nesbit

List of Publications by Year
in descending order

34	2,397	361296	414303
papers	citations	20	32
		h-index	g-index

34	34	34	3438
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	GATA3 haplo-insufficiency causes human HDR syndrome. Nature, 2000, 406, 419-422.	13.7	516
2	Mutations Affecting G-Protein Subunit Î±₁₁in Hypercalcemia and Hypocalcemia. New England Journal of Medicine, 2013, 368, 2476-2486.	13.9	340
3	Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. Nature Genetics, 2015, 47, 717-726.	9.4	310
4	Mutations in AP2S1 cause familial hypocalciuric hypercalcemia type 3. Nature Genetics, 2013, 45, 93-97.	9.4	242
5	Identification of 70 calcium-sensing receptor mutations in hyper- and hypo-calcaemic patients: evidence for clustering of extracellular domain mutations at calcium-binding sites. Human Molecular Genetics, 2012, 21, 2768-2778.	1.4	154
6	Characterization of GATA3 Mutations in the Hypoparathyroidism, Deafness, and Renal Dysplasia (HDR) Syndrome. Journal of Biological Chemistry, 2004, 279, 22624-22634.	1.6	145
7	Adaptor protein-2 sigma subunit mutations causing familial hypocalciuric hypercalcaemia type 3 (FHH3) demonstrate genotypeâ€“phenotype correlations, codon bias and dominant-negative effects. Human Molecular Genetics, 2015, 24, 5079-5092.	1.4	69
8	Towards personalised allele-specific CRISPR gene editing to treat autosomal dominant disorders. Scientific Reports, 2017, 7, 16174.	1.6	66
9	The Calcilytic Agent NPS 2143 Rectifies Hypocalcemia in a Mouse Model With an Activating Calcium-Sensing Receptor (CaSR) Mutation: Relevance to Autosomal Dominant Hypocalcemia Type 1 (ADH1). Endocrinology, 2015, 156, 3114-3121.	1.4	55
10	A G-protein Subunit-Î±11 Loss-of-Function Mutation, Thr54Met, Causes Familial Hypocalciuric Hypercalcemia Type 2 (FHH2). Journal of Bone and Mineral Research, 2016, 31, 1200-1206.	3.1	40
11	Cinacalcet for Symptomatic Hypercalcemia Caused by AP2S1 Mutations. New England Journal of Medicine, 2016, 374, 1396-1398.	13.9	38
12	Identification of a G-Protein Subunit-Î±11 Gain-of-Function Mutation, Val340Met, in a Family With Autosomal Dominant Hypocalcemia Type 2 (ADH2). Journal of Bone and Mineral Research, 2016, 31, 1207-1214.	3.1	36
13	Identification of a Second Kindred with Familial Hypocalciuric Hypercalcemia Type 3 (FHH3) Narrows Localization to a <3.5 Megabase Pair Region on Chromosome 19q13.3. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1947-1954.	1.8	34
14	Mouse model for inherited renal fibrosis associated with endoplasmic reticulum stress. DMM Disease Models and Mechanisms, 2017, 10, 773-786.	1.2	34
15	Allosteric Modulation of the Calcium-sensing Receptor Rectifies Signaling Abnormalities Associated with G-protein Î±-11 Mutations Causing Hypercalcemic and Hypocalcemic Disorders. Journal of Biological Chemistry, 2016, 291, 10876-10885.	1.6	31
16	Mutant Mice With Calcium-Sensing Receptor Activation Have Hyperglycemia That Is Rectified by Calcilytic Therapy. Endocrinology, 2017, 158, 2486-2502.	1.4	31
17	Personalised genome editing â€“ The future for corneal dystrophies. Progress in Retinal and Eye Research, 2018, 65, 147-165.	7.3	31
18	An N-Ethyl-N-Nitrosourea Induced Corticotropin-Releasing Hormone Promoter Mutation Provides a Mouse Model for Endogenous Glucocorticoid Excess. Endocrinology, 2014, 155, 908-922.	1.4	28

#	Article	IF	Citations
19	Topical siRNA delivery to the cornea and anterior eye by hybrid silicon-lipid nanoparticles. Journal of Controlled Release, 2020, 326, 192-202.	4.8	28
20	GÎ±11 mutation in mice causes hypocalcemia rectifiable by calcilytic therapy. JCI Insight, 2017, 2, e91103.	2.3	28
21	Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose in healthy and immunocompromised individuals. Journal of Infection, 2022, 84, 579-613.	1.7	21
22	X-linked hypoparathyroidism region on Xq27 is evolutionarily conserved with regions on 3q26 and 13q34 and contains a novel P-type ATPase. Genomics, 2004, 84, 1060-1070.	1.3	18
23	Role of Ca2+ and L-Phe in Regulating Functional Cooperativity of Disease-Associated â€œToggleâ€• Calcium-Sensing Receptor Mutations. PLoS ONE, 2014, 9, e113622.	1.1	18
24	Evaluation of the IgG antibody response to SARS CoV-2 infection and performance of a lateral flow immunoassay: cross-sectional and longitudinal analysis over 11 months. BMJ Open, 2021, 11, e048142.	0.8	17
25	Cinacalcet corrects hypercalcemia in mice with an inactivating GÎ±11 mutation. JCI Insight, 2017, 2, .	2.3	17
26	Mutation-Independent Allele-Specific Editing by CRISPR-Cas9, a Novel Approach to Treat Autosomal Dominant Disease. Molecular Therapy, 2020, 28, 1846-1857.	3.7	13
27	Mice with an N-Ethyl-N-Nitrosourea (ENU) Induced Tyr209Asn Mutation in Natriuretic Peptide Receptor 3 (NPR3) Provide a Model for Kyphosis Associated with Activation of the MAPK Signaling Pathway. PLoS ONE, 2016, 11, e0167916.	1.1	11
28	X-Linked Hypophosphatemia Attributable to Pseudoexons of the PHEX Gene. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3840-3844.	1.8	10
29	IgG antibody production and persistence to 6Âmonths following SARS-CoV-2 vaccination: A Northern Ireland observational study. Vaccine, 2022, 40, 2535-2539.	1.7	9
30	User experience of home-based AbC-19 SARS-CoV-2 antibody rapid lateral flow immunoassay test. Scientific Reports, 2022, 12, 1173.	1.6	3
31	Protein Analysis of the TGFBI^{R124H} Mouse Model Gives Insight into Phenotype Development of Granular Corneal Dystrophy. Proteomics - Clinical Applications, 2020, 14, e1900072.	0.8	2
32	Gene Editing for Corneal Stromal Regeneration. Methods in Molecular Biology, 2020, 2145, 59-75.	0.4	1
33	Successful Proof-of-Concept for Topical Delivery of Novel Peptide ALM201 with Potential Usefulness for Treating Neovascular Eye Disorders. Ophthalmology Science, 2022, 2, 100150.	1.0	1
34	Gene editing for the cornea. , 2022, , 81-100.		0